Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review
1. Viatris' Phase 3 study of MR-139 did not meet primary efficacy endpoint. 2. Chief R&D Officer indicated next steps may involve revising study plans. 3. MR-141 trial showed positive outcomes for presbyopia treatment over placebo. 4. Analysts project VTRS shares have a 1-year price target of $10. 5. Viatris shares fell 3.94% to $8.90 at publication time.